<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01176851</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-0915-PR-0031</org_study_id>
    <nct_id>NCT01176851</nct_id>
  </id_info>
  <brief_title>Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers</brief_title>
  <acronym>Gly1</acronym>
  <official_title>Pharmacokinetic, Randomized, Open-label, Single-dose, 3-way Cross-over Study of Intravenous and Inhaled Glycopyrrolate With or Without Charcoal Block Ingestion in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the pharmacokinetics, the absolute&#xD;
      bioavailability and the lung bioavailability of inhaled Glyco pMDI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma and urine pharmacokinetics of glycopyrrolate</measure>
    <time_frame>over 24 h post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung function parameters</measure>
    <time_frame>over 24 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular parameters</measure>
    <time_frame>over 24 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical chemistry and haematology, urinalysis</measure>
    <time_frame>over 24 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>during the whole study period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Glyco pMDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glyco pMDI 100 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glyco pMDI Charcoal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glyco pMDI 100 µg + charcoal block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glyco IV injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glyco solution for injection 100 µg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>Single administration of Glyco pMDI 100 µg</description>
    <arm_group_label>Glyco pMDI</arm_group_label>
    <other_name>CHF 5259</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>Single administration of Glyco pMDI 100 µg after charcoal ingestion</description>
    <arm_group_label>Glyco pMDI Charcoal</arm_group_label>
    <other_name>CHF 5259</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>Single intravenous injection of glycopyrrolate 100 µg</description>
    <arm_group_label>Glyco IV injection</arm_group_label>
    <other_name>Robinul Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females healthy volunteers aged 18-65 years;&#xD;
&#xD;
          2. Written informed consent obtained before the first trial related activity.&#xD;
&#xD;
          3. Able to understand the study procedures, the risks involved and ability to be trained&#xD;
             to use the devices correctly.&#xD;
&#xD;
          4. Body Mass Index (BMI) between 18.0 and 32.0 kg/m2;&#xD;
&#xD;
          5. Non- or ex-smokers who smoked &lt; 5 pack years;&#xD;
&#xD;
          6. Good physical and mental status;&#xD;
&#xD;
          7. Normal blood pressure and heart rate;&#xD;
&#xD;
          8. Electrocardiogram (ECG)considered as normal;&#xD;
&#xD;
          9. Results of laboratory tests within the normal ranges.&#xD;
&#xD;
         10. Lung function measurements within the normal ranges.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Blood donation (equal or more than 450 ml) or blood loss less than 8 weeks before&#xD;
             inhalation of the study medication;&#xD;
&#xD;
          2. Pregnant or lactating women or women of childbearing potential, UNLESS they are using&#xD;
             one or more of the acceptable methods of contraception. Male subjects not willing to&#xD;
             use an acceptable method of contraception.&#xD;
&#xD;
          3. Positive HIV1 or HIV2 serology;&#xD;
&#xD;
          4. Positive results from the Hepatitis serology which indicates acute or chronic&#xD;
             Hepatitis B or Hepatitis C;&#xD;
&#xD;
          5. Unsuitable veins for repeated venipuncture;&#xD;
&#xD;
          6. History of substance abuse or drug abuse within 12 months prior to screening visit or&#xD;
             with a positive urine drug screen at screening;&#xD;
&#xD;
          7. Clinically relevant abnormal laboratory values suggesting an unknown disease and&#xD;
             requiring further clinical investigation;&#xD;
&#xD;
          8. Clinically significant and uncontrolled cardiac, hepatic, renal, gastrointestinal,&#xD;
             endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with&#xD;
             successful completion of this protocol;&#xD;
&#xD;
          9. Participation in another clinical trial less than 8 weeks prior to inhalation of the&#xD;
             study medication; participation in another clinical trial using radioactive material&#xD;
             within 1 calendar year;&#xD;
&#xD;
         10. History of hypersensitivity to M3 Antagonists or any of the excipients contained in&#xD;
             any of the formulations used in the trial;&#xD;
&#xD;
         11. Any drug treatment, including prescribed or OTC medicines as well as vitamins,&#xD;
             homeopathic remedies etc, taken in the 14 days (2 months for enzyme-inducing or&#xD;
             enzyme-inhibiting drugs e.g., glucocorticoids, phenobarbital, isoniazid) preceding the&#xD;
             first intake of the study drug, with the exception of occasional paracetamol (maximum&#xD;
             2 g per day with a maximum of 10 g per 14 days for mild non-excluding conditions).&#xD;
&#xD;
         12. Treatment within the previous 3 months with any drug known to have a well defined&#xD;
             potential for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole).&#xD;
&#xD;
         13. Subjects who refuse to abstain from alcohol or caffeine containing foods or beverages&#xD;
             or grapefruit containing foods or beverages from 48 hour prior to the first intake of&#xD;
             study medication and for the entire duration of the study.&#xD;
&#xD;
         14. Heavy caffeine drinker.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dave Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicines Evaluation Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.chiesi.com/clinic/CSR_Synopsis_CCD-0915-PR-0031.pdf</url>
    <description>CSR Synopsis available in the Chiesi Clinical Study Register</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 5, 2010</study_first_submitted>
  <study_first_submitted_qc>August 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2010</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <name_title>Martine Cartier, Head of Clinical Operations</name_title>
    <organization>Chiesi Farmaceutici SpA</organization>
  </responsible_party>
  <keyword>None (study in healthy volunteers)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

